CRISPR Therapeutics shares are trading higher after Chardan Capital maintained a Buy rating on the stock and raised its price target from $110 to $112.
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics' stock price increased following Chardan Capital's decision to maintain a Buy rating and raise its price target from $110 to $112.
February 22, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics' stock price is likely to experience a short-term increase following the positive analyst rating and raised price target by Chardan Capital.
Analyst ratings and price target adjustments are significant indicators for stock price movements. Chardan Capital's decision to maintain a Buy rating and increase the price target for CRISPR Therapeutics suggests a strong vote of confidence in the company's future performance, likely leading to increased investor interest and a short-term rise in stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90